Literature DB >> 7848081

Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies.

C Mao1, D R Domenico, K Kim, D J Hanson, J M Howard.   

Abstract

OBJECTIVE: To improve our future care of the patient with exocrine pancreatic cancer by seeking, within the limitations of our present approaches, additional information on the growth and spread of the cancer and its influences on the patient.
DESIGN: Consecutive autopsies of all patients with exocrine pancreatic cancer were reviewed retrospectively by two surgeons and three pathologists. SETTINGS: Three teaching hospitals of the Medical College of Ohio, Toledo. MATERIALS: One hundred fifty-four consecutive autopsies of patients with exocrine pancreatic cancer during the period between 1952 and 1992.
RESULTS: Intrapancreatic metastases or multicentric cancers were found in 12 patients. In 32 patients, pancreatic cancer skipped the lymph nodes, primarily draining the respective areas of the pancreas to metastasize to the secondary chain of nodes. In 13 patients, pulmonary metastases occurred without hepatic metastasis. Intrapancreatic contiguous extension was identified in 34 patients. Carcinoma of the body and/or tail of the pancreas was characterized by transperitoneal as well as hematogenous dissemination to a greater extent than was carcinoma of the head of the pancreas. Seven of 11 small tumors (< 2 cm in diameter) were associated with remote metastases. Relatively severe chronic obstructive pancreatitis was found to have resulted from pancreatic carcinoma in 18 cases, whereas in seven patients, pancreatic carcinoma probably developed in preexisting chronic pancreatitis. Thromboembolic disease was found in 30 patients, more frequently in the patients with the mucin-producing tumors of the pancreatic body and tail. In 21 patients, the amount of ascites was not proportional to the severity of peritoneal dissemination, vessel invasion, or recognizable hepatic dysfunction. Thromboembolic disease, severe infection, stress ulcer, and acute hemorrhagic erosive gastroenteritis were frequent systemic complications contributing to death. Malnutrition in the form of cachexia was undoubtedly a major, even dominant, feature in many patients that could not be quantitated from this data.
CONCLUSIONS: Metastasizing cells frequently bypass the initial filters in lymph nodes, liver, or lung to become established in secondary or tertiary sites. Intrapancreatic metastases or multicentric tumors also may develop more frequently than generally has been recognized. Small cancers (< 2 cm in diameter) are often associated at autopsy with remote metastases. These facts would appear to limit the usefulness of the current staging of resected cancers of the pancreas. Cancers of the body or tail are characterized by transperitoneal and hematogenous spread to a greater extent than are those of the head. Anatomical studies often do not explain the cause or the extent of ascites associated with pancreatic adenocarcinoma. As previously indicated, chronic pancreatitis appears to be further confirmed as a precursor of pancreatic cancer.

Entities:  

Mesh:

Year:  1995        PMID: 7848081     DOI: 10.1001/archsurg.1995.01430020015001

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  37 in total

1.  An Unusual Finding on Screening Colonoscopy-Pancreatic Cancer.

Authors:  Diana L Franco; Suresh Pola; Derek Patel
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Metastatic pancreatic adenocarcinoma presenting as a large pelvic mass mimicking primary osteogenic sarcoma: a series of two patient cases.

Authors:  Nicholas P Webber; Sunil Sharma; Allie H Grossmann; Akram Shaaban; Kevin B Jones; Lester J Layfield; R Lor Randall
Journal:  J Clin Oncol       Date:  2010-08-16       Impact factor: 44.544

Review 3.  The lymphatic system and pancreatic cancer.

Authors:  Darci M Fink; Maria M Steele; Michael A Hollingsworth
Journal:  Cancer Lett       Date:  2015-12-29       Impact factor: 8.679

Review 4.  Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Authors:  Bernhard W Renz; Stefan Boeck; Falk Roeder; Christoph Trumm; Volker Heinemann; Jens Werner
Journal:  Visc Med       Date:  2017-02-10

5.  Five-Fraction Stereotactic Body Radiation Therapy (SBRT) and Chemotherapy for the Local Management of Metastatic Pancreatic Cancer.

Authors:  Jonathan W Lischalk; Aidan Burke; Jessica Chew; Christen Elledge; Marie Gurka; John Marshall; Michael Pishvaian; Sean Collins; Keith Unger
Journal:  J Gastrointest Cancer       Date:  2018-06

6.  A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer.

Authors:  Thomas J Howard; Joseph E Krug; Jian Yu; Nick J Zyromski; C Max Schmidt; Lewis E Jacobson; James A Madura; Eric A Wiebke; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2006-12       Impact factor: 3.452

7.  Inhibition of SCAMP1 suppresses cell migration and invasion in human pancreatic and gallbladder cancer cells.

Authors:  Sera Yang; Kyu Taek Lee; Jin Young Lee; Jong Kyoon Lee; Kwang Hyuck Lee; Jong Chul Rhee
Journal:  Tumour Biol       Date:  2013-05-08

8.  Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.

Authors:  C J Yeo; R A Abrams; L B Grochow; T A Sohn; S E Ord; R H Hruban; M L Zahurak; W C Dooley; J Coleman; P K Sauter; H A Pitt; K D Lillemoe; J L Cameron
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

9.  Bone Metastasis as the Only Metastatic Site in a Patient with Pancreatic Cancer following Distal Pancreatectomy.

Authors:  Muhammad Wasif Saif; Natalie Galanina; L Ravage-Mass; Kristin Kaley; Daniel Cornfeld; Lynne Lamb; David Chhieng
Journal:  Case Rep Med       Date:  2010-08-24

Review 10.  Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.

Authors:  Haojun Shi; Ji Li; Deliang Fu
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-07       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.